Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 1
1984 4
1985 1
1986 1
1987 7
1988 6
1989 4
1990 3
1991 5
1992 6
1993 11
1994 8
1995 13
1996 10
1997 2
1998 10
1999 5
2000 11
2001 6
2002 6
2003 11
2004 4
2005 7
2007 5
2008 2
2009 1
2011 2
2013 1
2014 3
2015 1
2017 1
2018 1
2025 1
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

159 results

Results by year

Filters applied: . Clear all
Page 1
Population Pharmacokinetic Analysis of Enalapril and Enalaprilat in Newly Treated Children with Heart Failure: Implications for Safe Dosing of Enalapril (LENA Studies).
Steichert M, Cawello W, Laeer S; LENA Consortium. Steichert M, et al. Clin Pharmacokinet. 2025 Jul;64(7):1103-1118. doi: 10.1007/s40262-025-01520-5. Epub 2025 Jun 3. Clin Pharmacokinet. 2025. PMID: 40461938 Free PMC article. Clinical Trial.
RESULTS: The analysed dataset comprised 173 enalapril and 268 enalaprilat serum concentrations from 34 subjects aged 25 days to 2.1 years (median age = 0.3 years). A combined model consisting of a one-compartment model for enalapril coupled with a one-compartment model for …
RESULTS: The analysed dataset comprised 173 enalapril and 268 enalaprilat serum concentrations from 34 subjects aged 25 days to 2.1 y …
Chronopharmacology of enalapril in hypertensive patients.
Sunaga K, Fujimura A, Shiga T, Ebihara A. Sunaga K, et al. Eur J Clin Pharmacol. 1995;48(6):441-5. doi: 10.1007/BF00194332. Eur J Clin Pharmacol. 1995. PMID: 8582461 Clinical Trial.
Serum concentrations of total drug (enalapril + enalaprilat, its active metabolite) during the day and night trials did not differ significantly at any time. However, serum enalaprilat tended to be higher and its maximum concentration greater in the day trial than i …
Serum concentrations of total drug (enalapril + enalaprilat, its active metabolite) during the day and night trials did not differ si …
Enalapril in heart failure.
Nicholls MG, Ikram H, Espiner EA, Webster MW, Fitzpatrick MA. Nicholls MG, et al. Br J Clin Pharmacol. 1984;18 Suppl 2(Suppl 2):163S-167S. doi: 10.1111/j.1365-2125.1984.tb02594.x. Br J Clin Pharmacol. 1984. PMID: 6099733 Free PMC article. Clinical Trial.
Acute administration of metoprolol and enalaprilat reduces insulin-stimulated thermogenesis and skin blood flow.
Tuominen JA, Eriksson JG, Koivisto VA. Tuominen JA, et al. J Intern Med. 1996 May;239(5):399-406. doi: 10.1046/j.1365-2796.1996.473824000.x. J Intern Med. 1996. PMID: 8642232 Clinical Trial.

Forearm blood flow (plethysmography) was lower with metoprolol compared to enalaprilat (2.1 +/- 0.2 vs. 2.8 +/- 0.4 mL per 100 mL min-1; P < 0.05). Glucose-plus-insulin-stimulated thermogenesis and total energy expenditures were reduced both by metoprolol (71 and 5.2%;

…
Forearm blood flow (plethysmography) was lower with metoprolol compared to enalaprilat (2.1 +/- 0.2 vs. 2.8 +/- 0.4 mL per 100 mL min …
Pharmacokinetics and pharmacodynamics of enalapril and its active metabolite, enalaprilat, at four different doses in healthy horses.
Gómez-Díez M, Muñoz A, Caballero JM, Riber C, Castejón F, Serrano-Rodríguez JM. Gómez-Díez M, et al. Res Vet Sci. 2014 Aug;97(1):105-10. doi: 10.1016/j.rvsc.2014.06.006. Epub 2014 Jun 12. Res Vet Sci. 2014. PMID: 24972864 Clinical Trial.
Serum concentrations of enalapril and enalaprilat were determined for pharmacokinetic analysis. Angiotensin-converting enzyme (ACE) activity, serum ureic nitrogen (SUN), creatinine and electrolytes were measured, and blood pressure was monitored for pharmacodynamic analysi …
Serum concentrations of enalapril and enalaprilat were determined for pharmacokinetic analysis. Angiotensin-converting enzyme (ACE) a …
High serum enalaprilat in chronic renal failure.
Elung-Jensen T, Heisterberg J, Kamper AL, Sonne J, Strandgaard S, Larsen NE. Elung-Jensen T, et al. J Renin Angiotensin Aldosterone Syst. 2001 Dec;2(4):240-5. doi: 10.3317/jraas.2001.038. J Renin Angiotensin Aldosterone Syst. 2001. PMID: 11881130 Free article. Clinical Trial.
The daily dose of enalapril was 10 (2.5-20) mg and the trough serum concentration of enalaprilat was 31.8 (<2.5-584.7)ng/ml. Ninety percent of the patients had higher serum concentrations of enalaprilat than has been reported in subjects with normal kidney functi …
The daily dose of enalapril was 10 (2.5-20) mg and the trough serum concentration of enalaprilat was 31.8 (<2.5-584.7)ng/ml. Ninet …
Influence of food on the bioavailability of enalapril.
Swanson BN, Vlasses PH, Ferguson RK, Bergquist PA, Till AE, Irvin JD, Harris K. Swanson BN, et al. J Pharm Sci. 1984 Nov;73(11):1655-7. doi: 10.1002/jps.2600731146. J Pharm Sci. 1984. PMID: 6097665 Clinical Trial.
Area under the serum concentration-time curves for enalaprilat and urinary recoveries for enalaprilat and total drug did not differ significantly between the fed and fasted conditions. The mean observed maximum serum concentration of enalaprilat was slightly …
Area under the serum concentration-time curves for enalaprilat and urinary recoveries for enalaprilat and total drug did not d …
Comparison of the pharmacokinetics of fosinoprilat with enalaprilat and lisinopril in patients with congestive heart failure and chronic renal insufficiency.
Greenbaum R, Zucchelli P, Caspi A, Nouriel H, Paz R, Sclarovsky S, O'Grady P, Yee KF, Liao WC, Mangold B. Greenbaum R, et al. Br J Clin Pharmacol. 2000 Jan;49(1):23-31. doi: 10.1046/j.1365-2125.2000.00103.x. Br J Clin Pharmacol. 2000. PMID: 10606834 Free PMC article. Clinical Trial.
AIMS: To compare the serum pharmacokinetics of fosinoprilat with enalaprilat and lisinopril after 1 and 10 days of dosing with fosinopril, enalapril and lisinopril. ...The difference between the AI for fosinoprilat (1.41) and enalaprilat (1.96) was statistically sig …
AIMS: To compare the serum pharmacokinetics of fosinoprilat with enalaprilat and lisinopril after 1 and 10 days of dosing with fosino …
Determination of enalapril and enalaprilat by enzyme linked immunosorbent assays: application to pharmacokinetic and pharmacodynamic analysis.
Matalka K, Arafat T, Hamad M, Jehanli A. Matalka K, et al. Fundam Clin Pharmacol. 2002 Jun;16(3):237-44. doi: 10.1046/j.1472-8206.2002.00087.x. Fundam Clin Pharmacol. 2002. PMID: 12165071 Clinical Trial.
We have developed two enzyme linked immunosorbent assay (ELISA) methods for determining enalapril and enalaprilat in plasma. In this study, 48 healthy subjects received an oral dose of either 10 or 20 mg of enalapril and plasma concentrations of enalapril and enalaprila …
We have developed two enzyme linked immunosorbent assay (ELISA) methods for determining enalapril and enalaprilat in plasma. In this …
Pharmacokinetics of enalapril in congestive heart failure.
Dickstein K. Dickstein K. Drugs. 1986;32 Suppl 5:40-4. doi: 10.2165/00003495-198600325-00006. Drugs. 1986. PMID: 3032562 Clinical Trial.
Enalapril maleate is a prodrug requiring in vivo hepatic esterolysis to yield the active diacid inhibitor enalaprilat. CHF results in changes in regional blood flow that may affect the gastrointestinal absorption, hepatic hydrolysis and renal excretion of enalapril and …
Enalapril maleate is a prodrug requiring in vivo hepatic esterolysis to yield the active diacid inhibitor enalaprilat. CHF results in …
159 results